Annovis Bio (ANVS) Corporate presentation summary

Development pipeline and clinical progress

• Lead asset buntanetap is in late-stage development for Alzheimer's and Parkinson's diseases, with pivotal Phase 3 trials ongoing or completed for both indications.

• Over 1,200 individuals have been treated with buntanetap as of April 2026, with pivotal AD trial enrollment nearly complete and PD open-label extension enrolling.

• Buntanetap is also being explored in combination therapies and for additional indications such as traumatic brain injury and stroke.

Clinical efficacy and safety

• Buntanetap demonstrated cognitive and motor improvements in biomarker-positive mild AD and PD patients, with robust efficacy across subgroups.

• Phase 3 PD study met primary and cognition endpoints in per-protocol and ITT populations, with consistent benefit in mild dementia and amyloid-positive patients.

• Safety profile is strong in both AD and PD populations, with low rates of serious adverse events and similar tolerability across APOE4 carriers and non-carriers.

Mechanism of action and biomarker engagement

• Buntanetap is a small molecule that targets RNA to inhibit production of multiple neurotoxic proteins implicated in neurodegeneration.

• Demonstrated dose-dependent reduction in APP, Aβ40, Aβ42 synthesis, and neurotoxic protein levels in both clinical and preclinical studies.

• Biomarker data show reductions in tau, pTau217, and inflammatory markers, supporting disease-modifying potential.